全文获取类型
收费全文 | 635篇 |
免费 | 50篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 16篇 |
妇产科学 | 7篇 |
基础医学 | 63篇 |
口腔科学 | 25篇 |
临床医学 | 65篇 |
内科学 | 129篇 |
皮肤病学 | 4篇 |
神经病学 | 38篇 |
特种医学 | 93篇 |
外科学 | 55篇 |
综合类 | 19篇 |
预防医学 | 48篇 |
眼科学 | 6篇 |
药学 | 27篇 |
中国医学 | 1篇 |
肿瘤学 | 96篇 |
出版年
2022年 | 4篇 |
2021年 | 6篇 |
2020年 | 6篇 |
2019年 | 6篇 |
2018年 | 12篇 |
2017年 | 7篇 |
2016年 | 21篇 |
2015年 | 7篇 |
2014年 | 11篇 |
2013年 | 25篇 |
2012年 | 13篇 |
2011年 | 18篇 |
2010年 | 21篇 |
2009年 | 31篇 |
2008年 | 14篇 |
2007年 | 27篇 |
2006年 | 17篇 |
2005年 | 18篇 |
2004年 | 25篇 |
2003年 | 12篇 |
2002年 | 11篇 |
2001年 | 14篇 |
2000年 | 9篇 |
1999年 | 11篇 |
1998年 | 30篇 |
1997年 | 32篇 |
1996年 | 30篇 |
1995年 | 26篇 |
1994年 | 18篇 |
1993年 | 20篇 |
1992年 | 8篇 |
1991年 | 6篇 |
1990年 | 17篇 |
1989年 | 18篇 |
1988年 | 20篇 |
1987年 | 25篇 |
1986年 | 10篇 |
1985年 | 10篇 |
1984年 | 8篇 |
1983年 | 6篇 |
1982年 | 4篇 |
1981年 | 6篇 |
1980年 | 5篇 |
1979年 | 4篇 |
1978年 | 6篇 |
1977年 | 5篇 |
1976年 | 4篇 |
1975年 | 4篇 |
1970年 | 5篇 |
1967年 | 5篇 |
排序方式: 共有699条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
The object of this study was to determine the effect of calcium carbonate or calcium phosphate supplements on dietary protein and fat utilization from low and high manganese diets. During the 63-day study, the 14 human adult subjects ate a constant laboratory controlled diet. In separate periods, subjects consumed the basal diet alone or with supplements of calcium carbonate, calcium carbonate plus manganese gluconate, calcium phosphate, or calcium phosphate plus manganese gluconate. Contrast analyses of data indicated that manganese gluconate supplementation of diets, when combined with either calcium phosphate or calcium carbonate, increased fecal losses of fat. When used as single supplements, both calcium phosphate and calcium carbonate depressed fecal fat loss in comparison with values when no supplements were used. Manganese gluconate supplements depressed fecal nitrogen losses calculated as a percentage of dry fecal weight. 相似文献
6.
Studies of proteins that inhibit tissue factor activity have generally been conducted using either an extracted tissue homogenate ("thromboplastin") or tissue factor protein reconstituted into phospholipid vesicles rather than with tissue factor expressed in cell membranes (its physiological environment). In the present study, a human fibroblast cell strain was used to evaluate the effects of lipoprotein associated coagulation inhibitor (LACI), placental anticoagulant protein (PAP), and apolipoprotein A-II (apo A-II) on human tissue factor in cell membranes. LACI was tested from 7.8 to 500 pmol/L on fibroblasts cultured at cell densities ranging from 3,500 to 9,925 cells/well, and caused a progressive inhibition of tissue factor activity. PAP was tested from 3.9 nmol/L to 1 mumol/L at cell densities ranging from 4,500 to 15,400 cells/well and caused up to 83% inhibition of tissue factor activity. Inhibition by these proteins appeared to be influenced by cell density as well as whether the cells were intact or disrupted. Apo A-II, up to 1 mumol/L, did not inhibit the tissue factor activity of intact or disrupted fibroblasts at any cell density examined even though it did inhibit the activity of tissue factor in phospholipid vesicles. Of these inhibitors of tissue factor-dependent activation of factor X, LACI was the most effective in suppressing the generation of factor Xa activity. The effects obtained with apo A-II are clearly dependent on the nature of the tissue factor preparation with which it is tested. The disparity between the inhibitory effect of apo A-II on the activity of tissue factor reconstituted into lipid vesicles and the absence of effect on the activity of tissue factor remaining in cell membranes serves to reemphasize the necessity of reexamining results obtained with model systems using as nearly physiological reagents as possible. 相似文献
7.
Myosin VIIA gene: heterogeneity of the mutations responsible for Usher syndrome type IB 总被引:8,自引:1,他引:8
Levy G; Levi-Acobas F; Blanchard S; Gerber S; Larget-Piet D; Chenal V; Liu XZ; Newton V; Steel KP; Brown SD; Munnich A; Kaplan J; Petit C; Weil D 《Human molecular genetics》1997,6(1):111-116
Usher syndrome is recognized as the most frequent cause of hereditary
deaf-blindness. Usher syndrome type I (USH1), the most severe form of the
disease, is characterized by profound congenital sensorineural deafness,
constant vestibular dysfunction, and retinitis pigmentosa of prepubertal
onset. This form is genetically heterogeneous and five loci (USH1A-E) have
been mapped thusfar. However, only the gene responsible for USH1 B (which
accounts for approximately 75% of USH1 cases) has been characterized. It
encodes a long-tailed unconventional myosin, myosin VIIA, with a predicted
2215 amino acid sequence. Primers covering the complete myosin VIIA coding
sequence as well as the 3' non coding sequence were designed, allowing
direct sequence analysis of each of the 48 coding exons and flanking splice
sites in seven patients affected by USH1. Four novel mutations were thereby
identified. The possibility should now be considered of a sequence-based
prenatal diagnosis in some of the families affected by this very severe
form of Usher syndrome.
相似文献
8.
9.
10.